Abstract
Measurement of bone mineral density (BMD) by dual X-ray absorptiometry (DXA) is a precise and accurate way to assess changes in BMD due to a variety of causes. However, the degree of bone loss may vary depending on the skeletal site examined. We postulated that interventions that change bone density would have a different effect on an area rich in trabecular bone, such as the distal femur, than on other subregions of the femur. Male Sprague-Dawley rats (325–350 g) were treated with triiodothyronine (T3), a bisphosphonate (pamidronate), or placebo for 21 days and then sacrificed. Ex vivo BMD of the proximal, distal, mid and total femur were measured by DXA. We found that mean BMD of hyperthyroid rats was significantly lower than controls at all femoral subregions. However, the difference in mean BMD between hyperthyroid and control rats was greatest at the distal femur (8.6%). In rats treated with bisphosphonate, mean BMD was significantly higher than controls at the proximal, distal, and total femur. The difference in mean BMD between controls and rats treated with bisphosphonate was greatest at the distal femur (31.8%). Furthermore, pamidronate (APD)-treated rats had lower mean mid-femur BMD than controls. We conclude that changes in BMD after treatment with bisphosphonate or T3 are greatest at the distal femur subregion, and that treatment with bisphosphonate may cause a slight reduction in midfemur BMD. Future studies examining changes in BMD in the rat femur after interventions that alter mineral metabolism should include subregion analysis.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Griffin MG, Kimble R, Hopfer W, Pacifici R (1993) Dual-energy x-ray absorptiometry of the rat: accuracy, precision, measurement of bone loss. J Bone Miner Res 8:795–800
Mitlak BH, Rodda CP, von Deck MD, Dobrolet NC, Neer RM, Nussbaum SR (1991) Pamidronate reduces PTH-mediated bone loss in a gene transfer model of hyperparathyroidism in rats. J Bone Miner Res 6:1317–1321
Ammann P, Rizzoli R, Slosman D, Bonjour J-P (1992) Sequential and precise in vivo measurement of bone mineral density in rats using dual-energy x-ray-absorptiometry. J Bone Miner Res 7:311–316
Rosen HN, Sullivan EK, Middlebrooks L, Zeind AJ, Gundberg C, Dresner-Pollak R, Maitland LA, Hock J, Moses AC, Greenspan SL (1993) Parenteral pamidronate prevents thyroid hormone-induced bone loss in rats. J Bone Miner Res 8:1255–1261
Kiebzak GM, Smith R, Howe JC, Sacktor B (1993) Bone mineral content in the senescent rat femur: an assessment using single photon absorptiometry. J Bone Miner Res 3:311–317
Seeman E, Wahner HW, Offord KP, Kumar R, Johnson WJ, Riggs BL (1982) Differential effects of endocrine dysfunction on the axial and the appendicular skeleton. J Clin Invest 69:1302–1309
Ongphiphadhanakul B, Jenis LG, Braverman LE, Alex S, Stein GS, Lian JB, Baran DT (1993) Etidronate inhibits thyroid hormone-induced bone loss in rats assessed by bone mineral density and messenger ribonucleic acid markers of osteoblast and osteoclast function. Endocrinology 133:2502–2507
Ongphiphadhanakul B, Alex S, Braverman LE, Baran DT (1992) Excessive L-thyroxine therapy decreases femoral bone mineral densities in the male rat: effect of hypogonadism and calcitonin. J Bone Miner Metab 7:1227–1231
Devogelaer JP, Esselinckx W, de Deuxchaisnes CN (1990) A randomized, controlled trial of APD (disodium pamidronate) given intravenously with and without sodium fluoride in involutional osteoporosis. J Bone Miner Res 5 (suppl 2):S252
Devogelaer JP, de Deuxchaisnes CN (1990) Treatment of involutional osteoporosis with the bisphosphonate APD (disodium pamidronate): non-linear increase of lumbar bone mineral density. J Bone Miner Res 5 (suppl 2):S251
Kimmel DB, Wronski TJ (1990) Nondestructive measurement of bone mineral in femurs from ovariectomized rats. Calcif Tissue Int 46:101–110
Geusens P, Dequeker J, Nijs J, Bramm E (1990) Effect of ovariectomy and prednisolone on bone mineral content in rats: evaluation by single photon absorptiometry and radiogrammetry. Calcif Tissue Int 47:243–250
Watts NB, Harris ST, Genant HK, Wasnich RD, Miller PD, Jackson RD, Licata AA, Ross P, Woodson III GC, Yanover MJ, Mysiw WJ, Kohse L, Rao MB, Steiger P, Richmond B, Chesnut III CH (1990) Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med 323:73–79
Fromm GA, Vega E, Plantalech L, Galich AM, Mautalen CA (1991) Differential action of pamidronate on trabecular and cortical bone in women with involutional osteoporosis. Osteoporosis Int 1:129–133
Price RI, Gutteridge DH, Stuckey BGA, Kent GN, Retallack RW, Prince RL, Bhagat CI, Johnston CA, Nicholson GC, Stewart GO (1993) Rapid, divergent changes in spinal and forearm bone density following short-term intravenous treatment of Paget's disease with pamidronate disodium. J Bone Miner Res 8: 209–217
Fenton AJ, Gutteridge DH, Kent GN, Price RI, Retallack RW, Shagat CI, Worth GK, Thompson RI, Watson IG, Barry-Walsh C, Matz LR (1991) Intravenous aminobisphosphonate in Paget's disease: clinical, biochemical, histomorphometric and radiological responses. Clin Endocrinol 34:197–204
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Rosen, H.N., Middlebrooks, V.L., Sullivan, E.K. et al. Subregion analysis of the rat femur: A sensitive indicator of changes in bone density following treatment with thyroid hormone or bisphosphonates. Calcif Tissue Int 55, 173–175 (1994). https://doi.org/10.1007/BF00425871
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00425871